QT Imaging Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 22, 2026, by QT Imaging Holdings, Inc., a Delaware corporation and emerging growth company. The filing primarily reports the entry into a material definitive agreement for a private placement of securities and the issuance of unaudited pro forma financial information as of September 30, 2025.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of common stock and warrants to Dr. Avi Katz, Chairman of the Board.
- Securities Issued: 24,107 shares of Common Stock and one Warrant to purchase up to 48,214 additional shares.
- Purchase Price: $6.43 per share (110% of the 5-day volume weighted average price).
- Gross Proceeds: Approximately $155,002.
- Use of Proceeds: Working capital purposes.
- Warrant Terms: Exercise price of $6.43; exercisable 6 months after issuance; 10-year term.
- Historical Context (Pro Forma): The filing references a prior October 2025 private placement yielding approximately $18,180,655 and the repayment of $5.36 million in debt and interest to Lynrock Lake Master Fund LP.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement and a Registration Rights Agreement dated January 22, 2026. Under the Registration Rights Agreement, the Company must file a registration statement for the resale of the securities within 30 days and have it declared effective within 60 days (or 90 days in the event of a full SEC review). Failure to allow resale for specific periods may trigger liquidated damages of 0.5% of the subscription amount per month.
Outlook, Risks, and Management Commentary
Management intends to use the net proceeds for working capital. The filing includes extensive forward-looking statements regarding the commercialization of the QT Imaging Breast Acoustic CT Scanner, product expansion, and strategic partnerships. Key risks identified include:
- Ability to sell and deploy the Breast Acoustic CT Scanner.
- Uncertainty in commercializing technology and moving sales to production levels.
- A material weakness in internal controls over financial reporting.
- Ability to obtain future financing and meet debt obligations.
- Market competition and supply chain unpredictability.
Investor Verification Checklist
- Verify the dilution impact of the 24,107 new shares and the potential 48,214 warrant shares on existing shareholders.
- Confirm the timeline for the registration statement filing and effectiveness as required by the Registration Rights Agreement.
- Review the unaudited pro forma financial statements (Exhibit 99.1) to understand the combined effect of the January 2026 and October 2025 capital raises and debt repayments.
- Assess the status of the material weakness in internal controls over financial reporting and the remediation timeline.
- Monitor the Company's ability to generate revenue from the QT Imaging Breast Acoustic CT Scanner as a primary business driver.